Selective Targeting Of Toxic Amyloid Beta Oligomers For The Treatment Of Alzheimer’s Disease Johanne Kaplan, PhD.
FESCH.TV INFORMIERT:
ProMIS Neurosciences Lead Product Candidate, PMN310, Shows Desired Target Binding Profile in Direct Comparison to Other Amyloid Beta-Directed Antibodies for Alzheimer’s Disease
Deinen Freunden empfehlen:
